Form 4: Teradyne Director Sells Shares Under 10b5-1 Plan

Teradyne, Inc. Director Marilyn Matz has reported the sale of common stock executed under a pre-arranged 10b5-1 trading plan.

Summary

• Director Marilyn Matz reported a transaction involving Teradyne, Inc. common stock.
• The transaction occurred on May 15, 2026.
• The sale was executed under a Rule 10b5-1 trading plan adopted on February 13, 2026.
• 800 shares of common stock were sold at a price of $338.98 per share.
• Following the transaction, Matz beneficially owns 19,040.675 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock transaction by a director under a pre-established plan, with no immediate indication of positive or negative company performance.

Negatives

• Director Marilyn Matz sold 800 shares of Teradyne common stock.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a director's stock transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those executed under Rule 10b5-1 plans, are routine disclosures for directors and officers. These plans allow insiders to sell shares during blackout periods or pre-determined schedules, aiming to avoid accusations of insider trading. The execution of such a plan by a director of Teradyne is a standard corporate governance practice.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director may be perceived by some shareholders as a negative signal, although the use of a 10b5-1 plan mitigates concerns about insider knowledge.
• Management: Reinforces adherence to corporate governance and insider trading regulations.

Key Dates

Keywords

Teradyne, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, SEC Filing